Mohamed Salem, MD
Interventional Cardiology · Bethlehem, PANPI 1366517336
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Hikma Pharmaceuticals USA accounts for 70.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $3,000 and has fallen 85.4% since, to $438 in 2025. That places this record below the midpoint for interventional cardiology clinicians in PA, where the typical reported total is $6,486.
Across 31 payments — averaging $137.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hikma Pharmaceuticals USA$3K
- Medtronic$312
- Rapid Medical Ltd$150
- Abiomed$137
- AstraZeneca$125
- E.r. Squibb & Sons, L.L.C.$116
- plus $415 from 6 others
What the payments were for
- Consulting fees$2,00047%
- Speaking & faculty fees$1,00024%
- Food & beverage$1,25529%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hikma Pharmaceuticals USA | 3 | $3,000 |
| Medtronic | 3 | $312 |
| Rapid Medical Ltd | 1 | $150 |
| Abiomed | 4 | $137 |
| AstraZeneca | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 5 | $116 |
| Abbott | 1 | $110 |
| Novartis | 6 | $93 |
| Boston Scientific | 4 | $88 |
| Edwards Lifesciences | 1 | $79 |
| Boehringer Ingelheim | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edarbi$3,000
- COREVALVE EVOLUT R$167
- TIGERTRIEVER 17 REVASCULARIZATION DEVICE$150
- COMANECI 17$150
- SilverHawk$136
- BREZTRI$125
- CARDIOMEMS$110
How this compares
$4,255 in reported general payments places this provider in the 35th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 145 | $173,874 |
| EntrestoSacubitril/Valsartan | 17 | $17,228 |
| XareltoRivaroxaban | 16 | $15,985 |
| Repatha SureclickEvolocumab | 14 | $12,624 |
| Metoprolol Succinate | 137 | $2,340 |
| Pitavastatin Calcium | 14 | $1,600 |
| Ezetimibe | 69 | $1,500 |
| ClopidogrelClopidogrel Bisulfate | 101 | $1,028 |
| Rosuvastatin Calcium | 64 | $995 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 24 | $898 |
| Torsemide | 29 | $801 |
| Amlodipine Besylate | 90 | $696 |
| Atorvastatin Calcium | 72 | $633 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 36 | $602 |
| Hydralazine Hcl | 31 | $574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $93 | $17,22817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Bethlehem
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1M
- William GrayWynnewood$753K
- Jon GeorgePhiladelphia$637K
- Shailendra SinghAllentown$470K
- Sanjog KalraPhiladelphia$444K
- James HarveyChambersburg$442K
- Taisei KobayashiPhiladelphia$384K
- Antonis PratsosBroomall$377K
- Ronald FieldsNew Hope$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.